Revolutionizing Cancer Care, One Patient at a Time
TVAX Biomedical is developing an exciting novel approach to cancer treatment (TVAX Immunotherapy®) that offers the opportunity of improved clinical outcomes for patients with any type of cancer, low toxicity and the potential for fundamentally changing the way cancer is treated
TVAX Immunotherapy is a personalized T cell therapy. It uses “killer” T cells that are manufactured from the blood of patients who have been vaccinated with their own neoantigen-producing cancer cells. This adoptive cell therapy is a two-step treatment that includes a vaccination pre-treatment, followed by activated T cell therapy to trigger the immune system to attack cancer in the body.
TVAX Immunotherapy
The lead TVAX clinical candidate, TVI-Brain-1, is being evaluated as a treatment for brain cancer (glioblastoma). The United States Food and Drug Administration granted TVAX with Fast Track Designation for its pivotal phase 2b TVI-Brain-1 clinical trial.